Posted by Michael Wonder on 18 Oct 2023
Health economic assessment of Beyfortus for the prevention of lower respiratory tract disease caused by respiratory syncytial virus
18 October 2023 - TLV has prepared a health economic assessment for the regions for the medicine Beyfortus (nirsevimab).
The assessment concerns preventive treatment in newborns and infants during their first RSV season.
